Pediatrix Medical Group (MD) Stock Overview
Provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MD Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pediatrix Medical Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.08 |
| 52 Week High | US$27.94 |
| 52 Week Low | US$14.05 |
| Beta | 0.65 |
| 1 Month Change | 1.08% |
| 3 Month Change | 15.19% |
| 1 Year Change | 88.97% |
| 3 Year Change | 83.47% |
| 5 Year Change | -17.94% |
| Change since IPO | 406.76% |
Recent News & Updates
Narrative Update • Aug 06
MD: Strong Results And Index Additions Will Still Face Hospital Fee Headwinds
Analysts have lifted their price target on Pediatrix Medical Group from $19.00 to $21.00, citing updated assumptions for slightly lower revenue growth, a modestly higher profit margin, a small change in discount rate, and an adjusted future P/E multiple. What’s in the News for Pediatrix Medical Group Pediatrix Medical Group reported second quarter results that management described as strong, with performance linked to recent acquisitions and same unit reimbursement metrics.
Narrative Update • Jul 09
MD: Rich Multiple And Softer Margins Will Temper Benefits From Ongoing Buybacks
Analysts have raised their price target on Pediatrix Medical Group from $21.33 to $23.17. They now apply slightly higher revenue growth assumptions and a modestly higher future P/E multiple, partially offset by a small adjustment to the discount rate and profit margin assumptions.Recent updates
Narrative Update • Aug 06
MD: Strong Results And Index Additions Will Still Face Hospital Fee Headwinds
Analysts have lifted their price target on Pediatrix Medical Group from $19.00 to $21.00, citing updated assumptions for slightly lower revenue growth, a modestly higher profit margin, a small change in discount rate, and an adjusted future P/E multiple. What’s in the News for Pediatrix Medical Group Pediatrix Medical Group reported second quarter results that management described as strong, with performance linked to recent acquisitions and same unit reimbursement metrics.Narrative Update • Jul 09
MD: Rich Multiple And Softer Margins Will Temper Benefits From Ongoing Buybacks
Analysts have raised their price target on Pediatrix Medical Group from $21.33 to $23.17. They now apply slightly higher revenue growth assumptions and a modestly higher future P/E multiple, partially offset by a small adjustment to the discount rate and profit margin assumptions.Narrative Update • Jun 24
MD: Hospital Fee Pressures Will Continue To Restrain Future Earnings Potential
The analyst price target for Pediatrix Medical Group remains at $19.00. The reaffirmed view reflects updated assumptions around discount rate, revenue growth, profit margin, and future P/E that analysts consider broadly consistent with prior expectations.Narrative Update • Jun 10
MD: Hospital Fee Pressures And Clinical Uncertainty Will Weigh On Future Returns
Analysts have kept the Pediatrix Medical Group price target steady at $19.00, citing only marginal updates to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially change their overall outlook. What's in the News Pediatrix Medical Group highlighted new research on probiotic use and necrotizing enterocolitis in preterm infants, finding that necrotizing enterocolitis rates rose in hospitals that sharply reduced probiotic use after 2023 FDA warnings and market withdrawals.Narrative Update • May 27
MD: Higher Discount Rate And Lower P/E Expectations Will Pressure Outlook
Analysts have kept their price target for Pediatrix Medical Group steady at $19.00, citing updated assumptions that include a slightly higher discount rate, modestly adjusted revenue growth and profit margin expectations, and a somewhat lower future P/E multiple. What's in the News Pediatrix Medical Group expanded in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine, rebranding the practice as Maternal-Fetal Medicine Specialists of Tennessee under the Pediatrix banner, with five locations in the Greater Nashville area and a team of four board-certified physicians and six advanced practice providers (Key Developments).
Narrative Update • May 04
MD: Future Returns Will Rely On Tennessee Expansion That Supports Buybacks
Analysts have raised their fair value estimate for Pediatrix Medical Group from $24.00 to $27.00, citing slightly adjusted assumptions for long term revenue growth, profit margin and future P/E levels as the main drivers of the updated price target. What's in the News Pediatrix expanded in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine, with the practice operating as Maternal-Fetal Medicine Specialists of Tennessee under the Pediatrix Medical Group banner at five locations in the Greater Nashville area (Key Developments).Narrative Update • Apr 20
MD: Future Returns Will Rely On Tennessee Expansion And Share Repurchases
Analysts have maintained their $24.00 price target on Pediatrix Medical Group, citing relatively stable assumptions for revenue growth, profit margin, and future P/E as the basis for this view. What's in the News Pediatrix expanded in Middle Tennessee through a partnership with Tennessee Maternal Fetal Medicine, rebranding the practice as Maternal Fetal Medicine Specialists of Tennessee under the Pediatrix Medical Group name and maintaining five locations across Greater Nashville.Narrative Update • Apr 05
MD: Future Earnings Upside Will Be Driven By Expansion And Buybacks
Analysts have kept their Pediatrix Medical Group price target steady at $24.00, noting only small adjustments in revenue growth, profit margin assumptions, and expected future P/E that offset each other in their updated models. What's in the News Pediatrix Medical Group expanded in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine, rebranding the practice as Maternal-Fetal Medicine Specialists of Tennessee under the Pediatrix banner and maintaining five locations across Greater Nashville.Narrative Update • Mar 22
MD: Ongoing Buybacks And Firmer Margins Will Support A Balanced Future Outlook
Analysts have trimmed their price target on Pediatrix Medical Group from $22.67 to $21.33, citing updated assumptions that now combine a lower revenue growth outlook and a slightly higher discount rate with a modestly stronger profit margin estimate and a revised future P/E of about 11x. What's in the News From October 1, 2025 to October 31, 2025, Pediatrix Medical Group repurchased 76,809 shares (0.09%) for US$1.12 million under the buyback announced on August 2, 2018, bringing total repurchases under this program to 13,668,040 shares (15.58%) for US$479.4 million (company buyback filing).Narrative Update • Mar 07
MD: Fair Outlook Will Rely On Stable Cash Flows And Ongoing Buybacks
Analysts have revised their price target on Pediatrix Medical Group from $21.00 to $19.00 as they incorporate a changed revenue growth outlook, slightly different profit margin expectations, and a lower assumed future P/E multiple. What's in the News From October 1, 2025 to December 31, 2025, Pediatrix Medical Group reported no share repurchases under the buyback announced on July 30, 2013.Narrative Update • Feb 21
MD: Higher Long Term Profitability Will Support Stronger Future Shareholder Returns
Analysts have revised their price target on Pediatrix Medical Group from $26.00 to $24.00, citing updated assumptions regarding discount rates, revenue growth, profit margins, and future P/E expectations. Valuation Changes Fair Value: Revised from $26.00 to $24.00, a reduction of $2.00 in the central valuation estimate.Narrative Update • Feb 07
MD: Fair Outlook Will Depend On Steady Cash Flows And Completed Buybacks
Analysts have kept their price target for Pediatrix Medical Group steady at $21.00, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that did not materially shift their overall view. Valuation Changes Fair Value: The fair value estimate remains unchanged at $21.00 per share.Narrative Update • Jan 24
MD: Stable Outlook Will Rely On Completed Buybacks And Steady Assumptions
Analysts have reiterated a US$21.00 price target for Pediatrix Medical Group, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only marginal tweaks to discount rate inputs. What's in the News Between July 1, 2025 and September 30, 2025, Pediatrix Medical Group reported no share repurchases under the buyback program announced on August 2, 2018.Narrative Update • Jan 10
MD: Completed Buybacks And Revised Assumptions Will Shape A Balanced Outlook
Analysts have raised their price target range for Pediatrix Medical Group from $13.00 to $21.00 per share, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E as the key drivers behind the new fair value estimate. What's in the News Pediatrix Medical Group reported that from July 1, 2025 to September 30, 2025 it repurchased 0 shares for $0 million under the buyback announced on August 2, 2018, while confirming completion of 13,591,231 shares repurchased in total, representing 15.49% for $478.28 million (Key Developments).Analysis Article • Jan 05
Pediatrix Medical Group (NYSE:MD) Is Doing The Right Things To Multiply Its Share Price
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Narrative Update • Dec 20
MD: Higher Long Term Profitability Should Drive Stronger Shareholder Returns
Analysts have raised their price target on Pediatrix Medical Group from 20 dollars to 26 dollars, citing expectations for stronger long term profitability and a higher justified earnings multiple, despite slightly moderating revenue growth assumptions and a modest increase in the discount rate. What's in the News The company reported that from July 1, 2025 to September 30, 2025, it repurchased 0 shares under the August 2, 2018 buyback program, and has now completed a total repurchase of 13,591,231 shares, representing 15.49% of shares outstanding for $478.28 million (Key Developments).Analysis Article • Dec 15
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narrative Update • Dec 06
MD: Stable Buybacks And Margins Will Support A Fair Future Outlook
Narrative Update Analysts modestly reaffirm their outlook on Pediatrix Medical Group, maintaining the price target effectively unchanged at approximately 22.67 dollars. Stable assumptions for discount rate, revenue growth, profit margins, and future valuation multiples continue to support the existing fair value framework.Narrative Update • Nov 22
MD: Improving Margins And Slightly Higher Risk Will Shape Fair Future Outlook
Analysts have raised their price target for Pediatrix Medical Group from $19.92 to $22.67. They cite improved profit margin expectations and a slightly higher discount rate as key factors driving this upward revision.Analysis Article • Nov 10
Pediatrix Medical Group's (NYSE:MD) Earnings Seem To Be Promising
Investors signalled that they were pleased with Pediatrix Medical Group, Inc.'s ( NYSE:MD ) most recent earnings...Narrative Update • Nov 05
MD: Share Repurchase Plan And Margin Gains Will Support Future Performance
Analysts have raised their price target for Pediatrix Medical Group from $16.71 to $19.92, citing improvements in projected revenue growth and profit margins. What's in the News The Board of Directors of Pediatrix Medical Group authorized a buyback plan on August 18, 2025.Analysis Article • Jul 31
Risks To Shareholder Returns Are Elevated At These Prices For Pediatrix Medical Group, Inc. (NYSE:MD)
With a median price-to-sales (or "P/S") ratio of close to 1x in the Healthcare industry in the United States, you could...New Narrative • May 28
Expanding NICU And Maternal Services Will Fuel US Healthcare Growth
Expanding service offerings, improved payer mix, and strategic acquisitions are driving revenue growth, earnings stability, and reduced earnings volatility.Analysis Article • May 22
Is Pediatrix Medical Group (NYSE:MD) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • May 01
Insufficient Growth At Pediatrix Medical Group, Inc. (NYSE:MD) Hampers Share Price
Pediatrix Medical Group, Inc.'s ( NYSE:MD ) price-to-sales (or "P/S") ratio of 0.5x may look like a pretty appealing...Analysis Article • Feb 18
These 4 Measures Indicate That Pediatrix Medical Group (NYSE:MD) Is Using Debt Extensively
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Jan 28
Returns At Pediatrix Medical Group (NYSE:MD) Are On The Way Up
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...Seeking Alpha • Nov 18
Pediatrix Medical Group: The Business Is Turning
Summary Pediatrix Medical Group has streamlined its focus to NICU physician staffing, leveraging its strong competitive advantage and high switching costs. Previous management issues with revenue cycle management have been resolved, ensuring smooth internal billing operations. The company has consistently exceeded earnings expectations, with current estimates still appearing conservative. With a clean balance sheet and low cyclicality, buying the stock below 10x earnings offers a solid margin of safety. Read the full article on Seeking AlphaAnalysis Article • Nov 06
Pediatrix Medical Group, Inc. (NYSE:MD) Shares Fly 27% But Investors Aren't Buying For Growth
Despite an already strong run, Pediatrix Medical Group, Inc. ( NYSE:MD ) shares have been powering on, with a gain of...Analysis Article • Oct 19
Here's Why Pediatrix Medical Group (NYSE:MD) Has A Meaningful Debt Burden
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Sep 28
We Like These Underlying Return On Capital Trends At Pediatrix Medical Group (NYSE:MD)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Analysis Article • Aug 07
Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified
Pediatrix Medical Group, Inc. ( NYSE:MD ) shareholders would be excited to see that the share price has had a great...Analysis Article • Jun 19
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • May 10
Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Mar 29
Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Analysis Article • Jan 10
Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pediatrix Medical Group fair value estimate is US$19.57...Analysis Article • Dec 25
Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 17x, you may...Analysis Article • Nov 14
Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Shareholder Returns
| MD | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 2.2% | -2.8% | 3.5% |
| 1Y | 89.0% | 42.4% | 20.5% |
Return vs Industry: MD exceeded the US Healthcare industry which returned 42.4% over the past year.
Return vs Market: MD exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| MD volatility | |
|---|---|
| MD Average Weekly Movement | 5.5% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 4,280 | Mark Ordan | www.pediatrix.com |
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program.
Pediatrix Medical Group, Inc. Fundamentals Summary
| MD fundamental statistics | |
|---|---|
| Market cap | US$2.10b |
| Earnings (TTM) | US$174.81m |
| Revenue (TTM) | US$1.95b |
12.3x
P/E Ratio1.1x
P/S RatioIs MD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MD income statement (TTM) | |
|---|---|
| Revenue | US$1.95b |
| Cost of Revenue | US$1.44b |
| Gross Profit | US$511.77m |
| Other Expenses | US$336.96m |
| Earnings | US$174.81m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.20 |
| Gross Margin | 26.24% |
| Net Profit Margin | 8.96% |
| Debt/Equity Ratio | 66.3% |
How did MD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/07 21:37 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pediatrix Medical Group, Inc. is covered by 26 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Matthew Gillmor | Baird |
| Matthew Borsch | BMO Capital Markets Equity Research |